Vicuron Pharmaceuticals Announces 40 Presentations at ICAAC
Highlighting Pipeline and Late-Stage Products KING OF PRUSSIA, Pa.,
Oct. 25 /PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals Inc.
(Nasdaq: MICU; Nuovo Mercato) today announced that researchers will
present 40 presentations comprising clinical and preclinical data
on the Company's pipeline of antibiotic and antifungal agents,
including its two late-stage products, anidulafungin and
dalbavancin, at the 44th Annual Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC) meeting in
Washington, D.C. this weekend. "Our traditionally strong scientific
presence at ICAAC demonstrates our pipeline and commitment to and
focus on an area of critical medical need," said George F. Horner
III, President and Chief Executive Officer of Vicuron. "Key
presentations will highlight the breadth of activity and potency of
dalbavancin against Staphylococcus and anidulafungin against
Candida biofilms. Ten presentations will highlight our lincomsamide
program, from which we expect a new clinical candidate to emerge in
the first half of next year. In addition, data from our
collaborations with Novartis in peptide deformylase inhibitors and
Pfizer in oxazolidinones also will be presented." Below are some of
the highlights from this year's ICAAC meeting. Anidulafungin ORAL
PRESENTATION: Anidulafungin Inhibits Candida albicans Biofilms In
Vitro, Sunday, October 31, 3:15 PM, Experimental Mycology, M. K.
Schinabeck, Case Western Reserve University/University Hospitals of
Cleveland, M-1141. POSTER PRESENTATIONS: 1. Candida glabrata
Resistance to Caspofungin During Therapy, Sunday, October 31, 1:30
PM, Clinical Mycology I, N.C. Villarreal, University of Texas
Health Science Center at San Antonio, M-1034. 2. Efficacy of
Anidulafungin (ANID) in Patients (Pts) with Azole- Refractory
Mucosal Candidiasis (ARMC), Sunday, October 31, 1:30 PM, Clinical
Mycology II, J. Vazquez, Wayne State University, M-1038. 3. Safety
and Pharmacokinetics of Anidulafungin in Pediatric Patients with
Neutropenia, Saturday, October 30, 10:00 AM, Pharmacokinetics of
Antifungal Drugs, T. J. Walsh, National Cancer Institute, A-34/30.
4. Clinical Efficacy Results from a Phase 3 Study of Anidulafungin
(ANID) versus Fluconazole (FLU) in HIV Negative Patients with
Esophageal Candidiasis (EC), Sunday, October 31, 1:30 PM, Clinical
Mycology I, J. Viljoen, Mediclinic Westdene, M-1023. Dalbavancin
POSTER PRESENTATIONS: 1. Antibacterial Effect of Dalbavancin
against MSSA, MRSA and VISA in an In Vitro Pharmacokinetic System,
Sunday, October 31, 3:00 PM, In Vitro Pk/PD Models, K. E. Bowker,
BCARE, A-1165/10. 2. Activity of Dalbavancin against Clinical
Isolates of Staphylococci and Streptococci from the U.S. and
Europe, Tuesday, Nov. 2, 10:00 AM, Cell Wall Inhibitors and
Anti-Gram Positive Drugs, R. K. Flamm, Focus Technologies,
E-2008/104. 3. Comparative Activity of Dalbavancin Tested against
7,771 Isolates from the U.S.A. and Europe (2003), Tuesday, Nov. 2,
10:00 AM, Cell Wall Inhibitors and Anti-Gram Positive Drugs, R. N.
Jones, The JONES Group, E-2009/105 4. The Pharmacokinetics of
Dalbavancin (DAL) in Subjects with Mild, Moderate or Severe Hepatic
Impairment (HI), Saturday, October 30, 10:00 AM, Pharmacokinetics
in Humans, J. A. Dowell, Vicuron Pharmaceuticals, A-19/15. Novel
Lincosamides/VIC-5555 ORAL PRESENTATION: All New Antimicrobial
Agents, VIC-105555: A Novel Lincosamide, Saturday, October 30,
10:00 AM, Oral presentation, Richard J. White, Ph.D. Vicuron
Pharmaceuticals. POSTER PRESENTATIONS: 1. Novel Antimicrobial
7-Methyl Lincosamides: Prolamide Analogs, Monday, November 1, 10:00
AM, Novel Lincosamides/VIC-105555, J. G. Lewis, Vicuron
Pharmaceuticals, F-1388/227. 2. Novel Antimicrobial 7-Methyl
Lincosamides: Pipecolamide Analogs, Monday, November 1, 10:00 AM,
Novel Lincosamides/VIC-105555, J. G. Lewis, Vicuron
Pharmaceuticals, F-1389/228. 3. Inhibition of Protein Synthesis and
Streptococcal Toxin Production by VIC-105555, Monday, November 1,
10:00 AM, Novel Lincosamides/VIC- 105555, P. S. Margolis, Vicuron
Pharmaceuticals, F-1390/229. 4. Bactericidal Activity,
Postantibiotic Effect and Frequency of Resistance of the Novel
Lincosamide VIC-105555, Monday, November 1, 10:00 AM, Novel
Lincosamides/VIC-105555, J. Blais, Vicuron Pharmaceuticals,
F-1391/230. 5. VIC-105555, a New Lincosamide with Improved In Vivo
Efficacy and Good In Vitro Activity, Monday, November 1, 10:00 AM,
Novel Lincosamides/VIC-105555, C. Park, Vicuron Pharmaceuticals,
F-1392/231. 6. Activity of VIC-105555 in Experimental Mouse Thigh
and Pneumonia Infections, Monday, November 1, 10:00 AM, Novel
Lincosamides/VIC- 105555, J. Blais, Vicuron Pharmaceuticals,
F-1393/232. 7. Superior Efficacy of the New Lincosamide VIC-105555
Versus Clindamycin in Experimental S. aureus and B. fragilis Rat
Pouch Infection, Monday, November 1, 10:00 AM, Novel
Lincosamides/VIC-105555, D. Jabes, Vicuron Pharmaceuticals,
F-1394/233. 8. Improved Pharmacokinetics of VIC-105555: Long
Half-Life and Large Volume of Distribution in Multiple Species,
Monday, November 1, 10:00 AM, Novel Lincosamides/VIC-105555, V.
Tembe, Vicuron Pharmaceuticals, F-1395/234. 9. Extensive Tissue
Distribution and Dose Response Pharmacokinetics of VIC-105555 in
Rats, Monday, November 1, 10:00 AM, Novel Lincosamides/VIC-105555,
V. Tembe, Vicuron Pharmaceuticals, F- 1396/235. Oxazolidinones and
Peptide Deformylase Inhibitors POSTER PRESENTATIONS: 1.
Thiadiazinone Phenyloxazolidinones with an Expanded Antibacterial
Spectrum, Monday, November 1, 10:00 AM, Novel Oxazolidinones, G. W.
Luehr, Vicuron Pharmaceuticals, F-1420/267. 2. LBM415, a New
Peptide Deformylase Inhibitor with Potent In Vitro Activity against
Drug-Resistant Bacteria, Tuesday, November 2, 8:30 AM, Peptide
Deformylase Inhibitors/LBM415, N. S. Ryder, Novartis Institutes for
BioMedical Research, Inc., F-1959/206. About Vicuron Vicuron
Pharmaceuticals is a biopharmaceutical company focused on
discovering, developing, manufacturing and commercializing vital
medicine for seriously ill patients. In May 2004, Vicuron received
an approvable letter from the FDA for its lead product
anidulafungin for the treatment of esophageal candidiasis. The
company's other lead product, dalbavancin, a novel intravenous
antibiotic for the treatment of serious Gram-positive infections,
has completed Phase 3 clinical trials. The Company's versatile
research engine integrates industry-leading expertise in functional
genomics, natural products discovery, mechanism-based drug design
and combinatorial and medicinal chemistry. These approaches are
yielding promising novel and next- generation compounds, many of
which are in the later stages of preclinical development. In
addition, the Company has research and development collaborations
with leading pharmaceutical companies, such as Pfizer and Novartis.
Forward-Looking Statements This news release contains
forward-looking statements that predict or describe future events
or trends. The matters described in these forward- looking
statements are subject to known and unknown risks, uncertainties
and other unpredictable factors, many of which are beyond Vicuron's
control. Vicuron faces many risks that could cause its actual
performance to differ materially from the results predicted by its
forward-looking statements, including the possibilities that
clinical trials and the results thereof might be delayed, or
unsuccessful, that the timing of the filing of any new drug
application or any amendment to a new drug application might be
delayed, that clinical trials might indicate that a product
candidate is unsafe or ineffective, that the FDA might require
additional information to be submitted and additional actions to be
taken before it will make any decision, that any filed new drug
application may not be approved by the FDA, that ongoing
proprietary and collaborative research might not occur or yield
useful results, that the pipeline may not yield a new clinical
candidate or a commercial product, that a third party may not be
willing to license our product candidates on terms acceptable to us
or at all, that competitors might develop superior substitutes for
Vicuron's products or market these competitive products more
effectively, that a sales force may not be developed as
contemplated and that one or more of Vicuron's product candidates
may not be commercialized successfully. The reports that Vicuron
files with the U.S. Securities and Exchange Commission contain a
fuller description of these and many other risks to which Vicuron
is subject. Because of those risks, Vicuron's actual results,
performance or achievements may differ materially from the results,
performance or achievements contemplated by its forward- looking
statement. The information set forth in this news release
represents management's current expectations and intentions.
Vicuron assumes no responsibility to issue updates to the
forward-looking matters discussed in this news release. DATASOURCE:
Vicuron Pharmaceuticals Inc. CONTACT: Dov A. Goldstein, M.D. of
Vicuron Pharmaceuticals Inc., +1-610-205-2312, ; or Hala Mirza of
WeissComm Partners, +1-212-204-2080, ; or Aline Schimmel of Burns
McClellan Inc., +1-212-213-0006, , both for Vicuron Pharmaceuticals
Inc. Web site: http://www.vicuron.com/
Copyright
